See more : Medaro Mining Corp. (MEDA.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Jasper Therapeutics, Inc. (JSPRW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jasper Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Herige (ALHRG.PA) Income Statement Analysis – Financial Results
- Tamilnadu Petroproducts Limited (TNPETRO.BO) Income Statement Analysis – Financial Results
- CBLT Inc. (CBBLF) Income Statement Analysis – Financial Results
- Metalex Ventures Ltd. (MXTLF) Income Statement Analysis – Financial Results
- Hecla Mining Company (HL-PB) Income Statement Analysis – Financial Results
Jasper Therapeutics, Inc. (JSPRW)
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.11M | 1.31M | 566.00K | 21.00K | 0.00 |
| Gross Profit | -1.11M | -1.31M | -566.00K | -21.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 51.79M | 34.63M | 25.42M | 15.88M | 3.62M |
| General & Administrative | 17.08M | 16.57M | 11.41M | 4.80M | 1.09M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.08M | 16.57M | 11.41M | 4.80M | 1.09M |
| Other Expenses | 0.00 | 586.00K | -80.00K | -111.00K | 0.00 |
| Operating Expenses | 68.86M | 51.20M | 36.83M | 20.68M | 4.45M |
| Cost & Expenses | 68.86M | 51.20M | 36.83M | 20.68M | 4.45M |
| Interest Income | 5.20M | 0.00 | 0.00 | 0.00 | 533.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.11M | 1.31M | 566.00K | 21.00K | 4.71M |
| EBITDA | -64.99M | -38.21M | -31.17M | -31.95M | -277.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.86M | -51.20M | -36.83M | -20.68M | -4.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.77M | 13.51M | 6.20M | -10.99M | -277.00K |
| Income Before Tax | -66.09M | -37.69M | -30.64M | -31.67M | -4.99M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.63M | -13.51M | -6.65M | -38.45K | -277.00 |
| Net Income | -64.47M | -24.17M | -23.98M | -31.67M | -4.99M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.18 | -6.63 | -21.05 | -114.30 | 0.00 |
| EPS Diluted | -6.18 | -6.63 | -21.05 | -114.30 | 0.00 |
| Weighted Avg Shares Out | 10.44M | 3.65M | 1.14M | 277.07K | 0.00 |
| Weighted Avg Shares Out (Dil) | 10.44M | 3.65M | 1.14M | 277.07K | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports